Cargando…
Primary therapy with single agent bortezomib as induction, maintenance, and re-Induction in patients with high risk myeloma: results of the ECOG E2A02 trial
Single agent bortezomib results in response rates of 51% in patients with newly diagnosed multiple myeloma (MM) and is touted to be especially effective in high-risk disease. We are the first to prospectively explore single agent bortezomib as primary therapy (response rate, maintenance and reinduct...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921007/ https://www.ncbi.nlm.nih.gov/pubmed/20535147 http://dx.doi.org/10.1038/leu.2010.129 |